MedTrace Logo

Traumatic Optic Neuropathy Treatment Trial 2

NCT03308448 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2024-03-08

No results posted yet for this study

Summary

After introducing intravenous erythropoietin (EPO) as an option for treatment of patients with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in this group of patients.

Conditions

  • Traumatic Optic Neuropathy

Interventions

DRUG

Recombinant human erythropoietin

Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group

Sponsors & Collaborators

  • Mashhad University of Medical Sciences

    collaborator OTHER

  • Tehran University of Medical Sciences

    collaborator OTHER

  • Iran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohsen B Kashkouli, MD · Iran University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-06
Primary Completion
2022-08-06
Completion
2023-03-02

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308448 on ClinicalTrials.gov